Presidio Medical Appoints Richard J. Buchholz to Board of Directors
Presidio Medical, Inc., a clinical-stage company focused on developing a groundbreaking neuromodulation platform, is excited to announce the appointment of Richard J. Buchholz to its Board of Directors. Rick currently serves as the Chief Financial Officer at Inspire Medical Systems,…
University Medical Devices Launches Innovative Nasal Lavage Collection Device for Faster, Higher-Sensitivity Samples
University Medical Devices (UMD), a leader in healthcare technology innovation, has announced the launch of its first specimen collection solution, MicroWash. Developed at the onset of the COVID-19 pandemic, MicroWash offers a comfortable and highly sensitive nasal lavage collection method,…
OnMed to Debut at CES 2025, Revolutionizing Healthcare Access for Underserved Communities
OnMed, a leading tech-enabled hybrid care company, is set to debut its innovative OnMed CareStation at CES 2025 in Las Vegas, Nevada. This breakthrough solution is transforming how underserved communities access essential healthcare, positioning OnMed as a pioneer in closing…
GE HealthCare Expands Effortless Recon DL Portfolio with Advanced Image Reconstruction
At the Radiological Society of North America (RSNA) 2024 Annual Meeting in Chicago, GE HealthCare (Nasdaq: GEHC) introduced three new advanced deep learning image processing and reconstruction solutions as part of its Effortless Recon DL portfolio. Designed to address the…
Hyperfine Highlights Clinical Study Results for Swoop® System at RSNA 2024
Hyperfine, Inc. (Nasdaq: HYPR), a leader in health technology, showcased data at the Radiological Society of North America (RSNA) 2024 Annual Meeting in Chicago, highlighting the growing use of AI-powered portable MR brain imaging. Eleven prominent institutions presented clinical studies…
LivaNova to Present Data at 2024 American Epilepsy Society Meeting
LivaNova PLC (Nasdaq: LIVN), a leading medical technology company, announced its participation in the American Epilepsy Society (AES) 2024 Annual Meeting, held December 6-10 in Los Angeles. The company will showcase its therapies and technologies for drug-resistant epilepsy through several…
GeneDx Expands Exome Testing Access for Pediatric Epilepsy with New Partners
GeneDx (Nasdaq: WGS), a leader in improving health outcomes through genomic insights, today announced Biogen (Nasdaq: BIIB), Praxis Precision Medicines (Nasdaq: PRAX), and Stoke Therapeutics (Nasdaq: STOK) as the founding partners of its Patient Access Program for pediatric epilepsy, offering…
Veterans’ Research Foundation Highlights CyPath® Lung’s Addition to Federal Supply Schedule
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive tests for early-stage cancer detection, will join Federal Supply System (FSS) officials today in a joint presentation. The event will highlight the Veterans Health Administration (VHA) award that…
ICON Survey Highlights Continued AI and Digital R&D Investment Amid Siloed Adoption
ICON plc (NASDAQ: ICLR), a global leader in clinical research powered by healthcare intelligence, today revealed the results of a recent global survey involving 101 biotech and pharma professionals from Europe and North America. The survey aimed to assess the…
Foundation Medicine Grants Support Organizations Addressing Biomarker Testing Disparities in Breast and Prostate Cancer
Foundation Medicine, Inc. has announced the awarding of two grants to organizations focused on reducing disparities in biomarker testing for breast and prostate cancer. These grants follow an open call for proposals in April 2024, where Foundation Medicine sought collaborations…
Hippocratic AI Partners with Nurses on Boards Coalition to Empower Nurses in Healthcare Tech
Hippocratic AI, the company developing the first safety-focused Large Language Model (LLM) for healthcare, has announced a strategic partnership with the Nurses on Boards Coalition (NOBC) to empower nurses in healthcare technology. This partnership reflects Hippocratic AI’s commitment to fostering…
Novocure Announces PANOVA-3 Phase 3 Trial Results for TTFields in Pancreatic Cancer
Novocure (NASDAQ: NVCR) announced that its pivotal Phase 3 PANOVA-3 trial successfully met its primary endpoint, showing a statistically significant improvement in median overall survival (mOS) compared to the control arm. The trial assessed the combination of Tumor Treating Fields…